Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings

Table 4 Summary of discordant mutations affecting choice of subsequent ART regimen

		Protease mutations		Reverse transcriptase mutations		Discordant phenotypic predictions		Mutation score		Predicted regimen of choice
IDR ID	Regimen	CAP103	IDR	CAP103	IDR	CAP103	IDR	CAP103	IDR	CAP103	IDR
036	TDF + XTC + EFV	None	None	M41L,D67N, K70R,M184V, K219Q V106M,V179D	A62V,K65R, D67N,M184V, K219Q V106M,V179D, F227FL	ABC: H AZT: H FTC: H 3TC: H TDF: L DOR: I EFV: H ETR: PL NVP: H RPV: L	ABC: H AZT: S FTC: H 3TC: H TDF: H DOR: H EFV: H ETR: PL NVP: H RPV: L	65 70 70 70 20 50 90 10 90 25	75 5 95 95 65 100 105 10 120 25	TDF + 3TC + DTG	AZT + 3TC + DTG
094	TDF + XTC + EFV	None	None	A62AV,K65KR,M184V,K219KN K103N,V106M	M184V K103N,V106M	ABC: H AZT: S FTC: H 3TC: H TDF: H	ABC: L AZT: S FTC: H 3TC: H TDF: S	70 -10 95 95 60	15 -10 60 60 -10	AZT + 3TC + DTG	TDF + 3TC + DTG

3TC lamivudine; ABC abacavir; AZT zidovudine; DTG dolutegravir; EFV efavirenz; FTC emtricitabine; H high-level resistance; I intermediate resistance; L low-level resistance; PL potential low-level resistance; TDF tenofovir; S susceptible; XTC lamivudine or emtricitabine
Bold values represent discordant results between CAP103 and IDR

ISSN: 1742-6405